Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized immunosuppressive drug monitoring after pediatric liver transplantation
ChiCTR1800015089Phase 3Completed
- Sponsor
- Renji Hospital
- Start
- Apr 2017
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of tacrolimus and cyclosporine (2 arms), sponsored by Renji Hospital. Primary endpoints: Incidence of acute rejection and Percentage of transplant-related infectious diseases. Started Apr 2017; status: completed.
02
Drugs
tacrolimuscyclosporine
Beyond the preview
Go deeper on ChiCTR1800015089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015089.